Cymabay Therapeutics, Inc. (NASDAQ:CBAY) tinted loss of -4.17% (-0.29 points) to US$6.66. The volume of 0.5 Million shares climbed down over an trading activity of 993.41 Million shares. EPS ratio determined by looking at last 12 month figures is -1.05. Over the same time span, the stock marked US$8.29 as its best level and the lowest price reached was US$1.15. The corporation has a market cap of US$280.05 Million.
Cymabay Therapeutics, Inc. (NASDAQ:CBAY)’s earnings per share has been growing at a 5.3 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -259.5 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 27.7 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
FT reports, The 6 analysts offering 12 month price targets for CymaBay Therapeutics Inc have a median target of 13.50, with a high estimate of 18.00 and a low estimate of 6.00. The median estimate represents a 102.70% increase from the last price of 6.66.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 5 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.6. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Innoviva, Inc. (NASDAQ:INVA) is worth US$1.34 Billion and has recently fallen -2.86% to US$12.22. The latest exchange of 1.09 Million shares is below its average trading activity of 852.55 Million shares. The day began at US$12.55 but the price moved to US$12.12 at one point during the trading and finally capitulating to a session high of US$12.58. The stock tapped a 52-week high of US$14.55 while the mean 12-month price target for the shares is US$12.8.
Currently, the stock carries a price to earnings ratio of 17.07, a price to book ratio of 0, and a price to sales ratio of 7.63. For the past 5 years, the company’s revenue has grown 40.4%, while the company’s earnings per share has grown 18.6%. With an institutional ownership near 68.3%, it carries an earnings per share ratio of 0.72.
According to Financial Times, The 5 analysts offering 12 month price targets for Innoviva Inc have a median target of 13.00, with a high estimate of 16.00 and a low estimate of 7.00. The median estimate represents a 6.38% increase from the last price of 12.22.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 1 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.2.